Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A Phase 2 Trial of SCRI-CAR19 Demonstrates Favorable Leukemia-Free Survival (LFS), with a Pilot Study of CD19-Expressing T-Cell Antigen Presenting Cells (CD19t T-APCs) Demonstrating Safety and Tolerability

Colleen Annesley, Kristy Seidel, Qian Vicky Wu, Corinne Summers, Alan S. Wayne, Anurag K. Agrawal, Michael A. Pulsipher, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Ashley L. Wilson, Wenjun Huang, Julie R. Park, Michael C. Jensen, Rebecca A. Gardner

Blood (2023) 142 (Supplement 1): 3467.

https://doi.org/10.1182/blood-2023-190525

Published: 2023

Journal Articles

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Colleen Annesley, Corinne Summers, Michael A. Pulsipher, Jodi L. Skiles, Amanda M. Li, Anant Vatsayan, Catherine Lindgren, Stephanie Mgebroff, Ashley Wilson, Wenjun Huang, Qian Vicky Wu, Josh Gustafson, Christopher Brown, Michael C. Jensen, Julie R. Park, Rebecca A Gardner

Blood (2021) 138 (Supplement 1): 470.

https://doi.org/10.1182/blood-2021-148881

Published: 2021

Journal Articles

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Colleen Annesley, MD, Rebecca Gardner, MD, Ashley Wilson, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Qian Vicky Wu, PhD, Adam Brand, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2019) 134 (Supplement_1): 223.

https://doi.org/10.1182/blood-2019-131346

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Colleen Annesley, MD, Rebecca Gardner, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4021.

https://doi.org/10.1182/blood-2018-99-112285

Published: 2018

Journal Articles

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Rebecca Gardner, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Kaelin Crews, Lauren Huang, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Karen Spratt, PhD, Josh Gustafson, PhD, Adam Johnson, PhD, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 278.

https://doi.org/10.1182/blood-2018-99-113126

Published: 2018

Journal Articles

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Rebecca A. Gardner, Olivia Finney, Colleen Annesley, Hannah Brakke, Corinne Summers, Kasey Leger, Marie Bleakley, Christopher Brown, Stephanie Mgebroff, Karen S. Kelly-Spratt, Virginia Hoglund, Catherine Lindgren, Assaf P. Oron, Daniel Li, Stanley R. Riddell, Julie R. Park, Michael C. Jensen

Blood (2017) 129 (25): 3322–3331.

https://doi.org/10.1182/blood-2017-02-769208

Published: 2017

Includes: Supplemental data

Journal Articles

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Smithers, MS, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Christopher Brown, Stephanie Mgebroff, MS, Catherine Lindgren, Karen Spratt, PhD, Assaf Oron, PhD, Daniel Li, PhD, Marie Bleakley, MDPhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 219.

https://doi.org/10.1182/blood.V128.22.219.219

Published: 2016

Journal Articles

T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse

Rebecca A Gardner, MD, Julie R Park, MD, Karen S Kelly-Spratt, PhD, Olivia Finney, PhD, Hannah Smithers, Virginia Hoglund, Christopher Brown, Stephanie Mgebroff, MS, Catherine G. Lindgren, Assaf P Oron, PhD, Marie Bleakley, MD, Michael C Jensen, MD

Blood (2014) 124 (21): 3711.

https://doi.org/10.1182/blood.V124.21.3711.3711

Published: 2014

Journal Articles

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Wilson Lam, MD, Jan Storek, MD PhD, Nizar J Bahlis, MD, Christopher Brown, MD, Peter Duggan, MD FRCPC, Michelle Geddes, MD FRCPC, Mary Lynn Savoie, MD FRCPC, Mona Shafey, MD FRCPC, Douglas A. Stewart, MD FRCPC, Andrew Daly, MD FRCPC

Blood (2014) 124 (21): 3901.

https://doi.org/10.1182/blood.V124.21.3901.3901

Published: 2014

Journal Articles

Fludarabine Metabolite Level On Day Zero Does Not Affect Outcomes Of Hematopoietic Cell Transplantation In Patients With Normal Renal Function

Cameron D. Griffiths, MD, Ella S.M Ng, MSc., Bill Kangarloo, MSc., Tyler S Williamson, PhD, Reanne Booker, BSc, MSN, NP, Ping Yue, MD, Peter Duggan, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Christopher Brown, MD, Andrew Daly, MD, FRCPC, James A Russell, MD, Jan Storek, MD, PhD

Blood (2013) 122 (21): 2116.

https://doi.org/10.1182/blood.V122.21.2116.2116

Published: 2013

Journal Articles

FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.

Andrew Daly, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Ahsan Chaudhry, MD, Nizar J Bahlis, MD, FRCPC, Christopher Brown, MD, FRCPC, Peter Duggan, MD, FRCPC, Michelle Geddes, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Jan Storek, MD, PhD, Maggie Yang, James A. Russell, MD, FRCPC

Blood (2009) 114 (22): 3384.

https://doi.org/10.1182/blood.V114.22.3384.3384

Published: 2009

Journal Articles

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

James A. Russell, FRCP, Leanne Kmet, MSc, Mary Lynn Savoie, MD, Nizar J. Bahlis, MD, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, Michelle Geddes, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Christopher Brown, MD, Jan Storek, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 5398.

https://doi.org/10.1182/blood.V108.11.5398.5398

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

James A. Russell, FRCP, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, M. Ahsan Chaudhry, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, Christopher Brown, MD, Alexander Balogh, MD, Jan Storek, MD, Michelle Geddes, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3009.

https://doi.org/10.1182/blood.V108.11.3009.3009

Published: 2006

Journal Articles

Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.

Mary Lynn Savoie, MD, Alexander Balogh, MD, Ahsan Chaudhry, MD, Douglas A. Stewart, MD, Nizar J. Bahlis, MD, Jan Storek, MD,PhD, Christopher Brown, MD,PhD, Diana Quinlan, RN, Leanne Kmet, PhD, Loree M. Larratt, MD, A. Robert Turner, MD, James A. Russell, FRCPE

Blood (2006) 108 (11): 3010.

https://doi.org/10.1182/blood.V108.11.3010.3010

Published: 2006

Journal Articles

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Loree M. Larratt, MD, Michelle Geddes, MD, Jan Storek, MD, Mary Lynn Savoie, MD, Christopher Brown, MD, Nizar J. Bahlis, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3159.

https://doi.org/10.1182/blood.V108.11.3159.3159

Published: 2006

Journal Articles

High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.

Michelle Geddes, MD, Shahbal B. Kangarloo, PhD, Farrukh Naveed, BSc, Quinlan M. Diana, RN, Ahsan Chaudhry, MD, Mary Lynn Savoie, MD, Nizar J. Bahlis, MD, Douglas A. Stewart, MD, Christopher Brown, MD, PhD, Jan Storek, MD, PhD, Borje Andersson, MD, PhD, James A. Russell, MA, MB, B. Chir

Blood (2006) 108 (11): 313.

https://doi.org/10.1182/blood.V108.11.313.313

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Michelle Geddes, MD, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Alexander Balogh, MD, Jan Storek, MD, Christopher Brown, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3140.

https://doi.org/10.1182/blood.V108.11.3140.3140

Published: 2006

Journal Articles

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

James A. Russell, FRCP, Loree M. Larratt, MD, A. Robert Turner, MD, M. Ahsan Chaudhry, MD, Oluyeme Jeje, MD, Donald Morris, MD, Christopher Brown, MD, Diana M. Quinlan, BN, Douglas A. Stewart, MD

Blood (2006) 108 (11): 2865.

https://doi.org/10.1182/blood.V108.11.2865.2865

Published: 2006

Journal Articles

Fludarabine-Busulfan Conditioning and In Vivo T-Cell Depletion with Reduced Dose of ATG Followed by Allografting Induces Durable Responses in Patients with Advanced Multiple Myeloma with No Grade III-IV aGvHD.

Nizar J. Bahlis, MD, Douglas A. Stewart, MD, Mary Lynn Savoie, MD, Christopher Brown, MD, Andrew Daly, MD, Ahsan Chaudhry, MD, Jan Storek, MD, PhD, James A. Russell, MBBChir, FRCPE

Blood (2006) 108 (11): 3029.

https://doi.org/10.1182/blood.V108.11.3029.3029

Published: 2006

NARROW

A Phase 2 Trial of SCRI-CAR19 Demonstrates Favorable Leukemia-Free Survival (LFS), with a Pilot Study of CD19-Expressing T-Cell Antigen Presenting Cells (CD19t T-APCs) Demonstrating Safety and Tolerability

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Fludarabine Metabolite Level On Day Zero Does Not Affect Outcomes Of Hematopoietic Cell Transplantation In Patients With Normal Renal Function

FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

Fludarabine-Busulfan Conditioning and In Vivo T-Cell Depletion with Reduced Dose of ATG Followed by Allografting Induces Durable Responses in Patients with Advanced Multiple Myeloma with No Grade III-IV aGvHD.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only